Register here to attend Alex Zhavoronkov's AC seminar taking place in person at 700 University Avenue or online via Zoom.
Abstract
In this talk we will cover the application of AI to disease modeling, target discovery, indication prioritization, indication expansion, and small molecule drug design. We will review several case studies and the current state of the industry. We will also discuss the limitations, current industry bottlenecks and opportunities for further development in drug discovery. We will also discuss the applications of generative AI to development of multi-species multi-omics life models for aging research and fundamental biological research.
Bio
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leading clinical-stage biotechnology company developing next-generation generative artificial intelligence and robotics platforms for drug discovery. Since 2014, he has invented critical technologies in the field of generative artificial intelligence and reinforcement learning (RL) for the generation of novel molecular structures with the desired properties and the generation of synthetic biological and patient data. He also pioneered the applications of transformers and other deep learning technologies for the prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership, Insilico raised over $400 million in multiple rounds from expert biotechnology, healthcare, and financial investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Since 2021, the company nominated 18 preclinical candidates, started 6 human clinical trials, and entered Phase II with an AI-discovered novel target and AI-designed novel molecule. By 2023, 10 out of the top 20 pharmaceutical companies used a part of the Pharma.AI software suite, and the IND-stage cancer program was sold in a deal with $80 million upfront as a testament to the quality and novelty of the AI-generated molecule. Prior to founding Insilico, he worked in senior roles at ATI Technologies (GPU company acquired by AMD). Since 2012, he has published over 200 peer-reviewed research papers with over 30 papers in the field of generative adversarial networks, generative reinforcement learning, and multi-modal transformers, and 3 books, including "The Ageless Generation: How Biomedical Advances Will Transform the Global Economy"(Macmillan, 2013). He serves on the advisory or editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, and Frontiers in Genetics, and founded and co-chairs the Annual Aging Research and Drug Discovery (10th Annual in 2023), the world's largest event on aging research in the biotechnology industry. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
About the AC Seminar Series
The Acceleration Consortium (AC) seminar series will explore perspectives on the future of AI for science, present cutting-edge research findings, enable collaborations, and offer training and upskilling opportunities. Presented both in-person and online, these seminars will host a diverse set of speakers on topics related to accelerated discovery across three tracks:
AC Distinguished Seminars: Leaders in the autonomous discovery community will share their findings and perspectives that are helping to shape future directions and address key challenges. These will be delivered in a hybrid format at University of Toronto.
AC Early Career Seminars: Early career researchers will present results from their latest publications, taking a technical dive into findings, methods, and tools. These will be delivered in a hybrid format at University of Toronto.
AC Virtual Training Seminars: Instructors will provide standalone introduction lectures and hands-on tutorials on topics related to self-driving labs with an emphasis on principles, literacy, and skills. These will be delivered virtually.
Do you have a suggestion for a talk? We welcome your ideas for potential speakers from diverse career stages and backgrounds.
